{"entity":{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","aka":[],"tldr":"New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated.","summary":"Median annual US launch price of new oncology drugs rose from ~$100,000 (2010) to over $200,000 (2020s), with weak correlation between price and clinical benefit (Vokinger, Lancet Oncol 2020). List versus net price (rebates, 340B) obscures costs; Medicare negotiation under the Inflation Reduction Act (2022) began with imbruvica (ibrutinib) among the first ten drugs (prices effective 2026) and caps Part D out-of-pocket at $2,000 (2025). Value frameworks: ASCO Value Framework, ESMO-MCBS, NCCN Evidence Blocks, ICER cost-effectiveness reviews, NICE thresholds (£25,000-35,000/QALY since 2 April 2026, raised from £20,000-30,000; Cancer Drugs Fund for managed access), Germany's AMNOG benefit assessment. International reference pricing, biosimilar/generic entry (imatinib price fell >90% after 2016 US generics), compulsory licensing and tiered pricing shape global access. Transparency initiatives (WHO 2019 resolution, US hospital price transparency rule) have had limited effect on net prices.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Prescription_drug_prices_in_the_United_States","links":[{"label":"Vokinger 2020 price vs benefit (Lancet Oncol)","url":"https://doi.org/10.1016/S1470-2045(20)30139-X"},{"label":"ICER","url":"https://icer.org/"},{"label":"CMS Medicare Drug Price Negotiation","url":"https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation"}],"tags":["gap-fill","policy"],"related":["financial-navigation","global-oncology-access","biosimilar","accelerated-approval"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["financial-toxicity","who-essential-medicines"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-vokinger-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/drug-price-transparency/","neighbours":{"technology":[{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/"}],"term":[{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/"},{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/"},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"},{"id":"china-vbp-nrdl","kind":"term","name":"China National Reimbursement Drug List negotiation and volume-based procurement","route":"/terms/china-vbp-nrdl/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/"},{"id":"novartis-glivec-ruling","kind":"term","name":"Novartis v. Union of India (Glivec, 2013)","route":"/terms/novartis-glivec-ruling/"},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/"}],"paper":[{"id":"paper-vokinger-lancet-oncol","kind":"paper","name":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","route":"/key-papers/paper-vokinger-lancet-oncol/"}],"idea":[{"id":"idea-cost-inflation-rebates-commercial","kind":"idea","name":"Extend Medicare's inflation rebates to employer plans","route":"/ideas/idea-cost-inflation-rebates-commercial/"},{"id":"idea-cost-transparent-generic-pricing","kind":"idea","name":"Transparent cost-plus pricing for every oral oncology generic","route":"/ideas/idea-cost-transparent-generic-pricing/"}],"collection":[{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/"}]}}